NCT01222780 2020-01-18
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
Acrotech Biopharma Inc.
NYU Langone Health
Children's Oncology Group
Dana-Farber Cancer Institute